Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant dendritic-cell immunotherapy plus temozolomide in newly diagnosed glioblastoma
2024-515291-13-00Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Nov 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of WT1 LAMP mRNA dendritic cell vaccine in glioblastoma (GBM), sponsored by Antwerp University Hospital. Primary endpoints: Overall survival and Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
WT1 LAMP mRNA dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-515291-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515291-13-00.